AN2 Therapeutics (ANTX)
Develops boron-chemistry medicines for hematologic disease, infectious disease, and oncology.
Something off on this page? Send us feedback.
Develops boron-chemistry-based small-molecule medicines across hematologic disease, infectious disease, and oncology. It remains a clinical-stage developer, with epetraborole and AN2-502998 among its programs and no approved products.
Develops small-molecule medicines from a boron-chemistry platform, with programs in hematologic disease, infectious disease, and oncology. The pipeline includes oral epetraborole for phlebotomy-dependent polycythemia vera, an investigator-initiated study in M. abscessus lung disease, and AN2-502998 for chronic Chagas disease.
Work spans early research and clinical development rather than sales of approved products. The company has not demonstrated commercial manufacturing, regulatory approval, or sales and marketing capability.
Its prior EBO-301 study in MAC lung disease was discontinued after its results, and development now depends on advancing separate programs through clinical testing and regulatory review.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 19, 2026 | Guggenheim | Initiate | Buy | $9 | ||
| May 14, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform | $5 | $9 |
| Nov 18, 2024 | TD Cowen | Downgrade | Buy | Hold |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $78.4M · Total debt $0 · Total assets $81.7M · Shareholders' equity $75.9M
- Revenue
- $0
- Operating income
- −$8.9M
- Net income
- −$8.2M
No dividends on record.
| Institutions52 holders · as of Mar 31, 2026 | 58.02% | 21.89M shares | |
| Insiders13 holders · as of Sep 2, 2026 | 17.35% | 6.55M shares | |
| Strategic holders2 holders · as of Mar 13, 2026 | 10.95% | 4.13M shares | |
| Otherremainder | 13.68% | 5.16M shares |
37.74M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BML Investment Partners, L.P.Institution | 15.24% | 5.75M | 13Gfiled Feb 13, 2025 ↗ |
Vivo Capital, LLCInstitution | 8.36% | 3.15M | 13Fas of Mar 31, 2026 |
Braden Michael LeonardInsider10 percent owner | 8.00% | 3.02M | Form 4filed Jun 16, 2025 ↗ |
Vivo Opportunity Fund Holdings, L.P.Institution | 7.59% | 2.86M | 13Gfiled Mar 13, 2026 ↗ |
Coastlands Capital LPInstitution | 7.46% | 2.82M | 13Gfiled Jun 4, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Margaret M. FitzPatrick | director | +2,098 | $5.53 |
| Aug 17, 2026 | Robin Shane Readnour | director | −35,402 | $6.01 |
| Jul 8, 2026 | Joshua M. Eizen | officer: See Remarks | −5,945 | $4.17 |
| May 29, 2026 | Sarah Joanne Williams | officer: Principal Accounting Officer | −265 | $4.43 |
| Mar 3, 2026 | Sarah Joanne Williams | officer: Principal Accounting Officer | −327 | $1.06 |
- Incyte
Approved JAK inhibitor therapy for polycythemia vera
- Novartis (ADR)
Marketed PI3K-alpha inhibitor for PIK3CA-mutated breast cancer
- Rogers
Marketed PI3K-alpha-targeting therapy for PIK3CA-mutated breast cancer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics | $6.30 | +6.06% | $214.3M | — | — | — | — |
| Incyte | $126.20 | −2.03% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Novartis (ADR) | $161.86 | −0.36% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Rogers | $124.10 | −0.30% | $2.22B | 71.7 | 29.3 | 2.7 | +6.9% |
| Median | 24.5 | 29.3 | 4.5 | +6.9% |